Hendrixx et al. demonstrated that IL22 treatment improved NAFLD in wild-type mice, but not in Reg3y-/-, which linked the benefits of this cytokine to antimicrobial peptide production and gut microbiota29. Here, IL22 is linked to metabolic dysfunction-associated steatotic liver disease.